GSK
NYSE · Healthcare
GSK plc
$54.90
+1.95 (+3.68%)
GSK News15 articles
Pfizer Shares Dip as GSK RSV Vaccine Gains Ground, Eliquis Data Provides Support
Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.
GSK Expands Share Repurchases, Outlines 2026 Growth Strategy Under New CEO
GSK has acquired 650,000 shares for treasury and published its 2025 annual report, showing £32.7B in turnover. CEO Luke Miels forecasts continued profitable growth for 2026.
GSK Advances Pipeline with $2.2B RAPT Buy, Continues Share Repurchases
GSK shares gained after finalizing its $2.2 billion purchase of RAPT Therapeutics, acquiring a Phase IIb food allergy candidate, and disclosed further share repurchases as part of an ongoing program.
GSK Shares Dip Amid Oil Price Surge, Buyback Activity and FDA Decision in Focus
GSK's stock declined alongside the FTSE 100 as geopolitical tensions drove oil prices higher, reigniting inflation concerns. The pharmaceutical firm also reported recent buyback activity and faces a crucial FDA verdict later this month.
GSK Shares Dip Amid Oil Price Surge, Buyback Activity and FDA Decision in Focus
GSK's stock declined alongside the FTSE 100 as geopolitical tensions drove oil prices higher, reigniting inflation concerns. The company also reported fresh share repurchase activity.
GSK Shares Edge Higher Amid Buyback Activity and Consultancy Fallout
GSK plc shares gained 0.4% in early London trading while the company executed share buybacks and cut ties with consultancy Global Counsel amid reputational concerns.
GSK Stock Dips on Ex-Dividend Date and Arexvy Vaccine Data Release
GSK shares declined 0.4% in early London trading, influenced by the stock going ex-dividend and the release of new real-world effectiveness data for its respiratory syncytial virus vaccine Arexvy.
GSK Gains on EU Asthma Drug Approval and £450M Share Repurchase
GSK shares advanced after the European Commission approved its asthma drug Exdensur and the company launched a £450 million share repurchase. New data also highlighted the effectiveness of its RSV vaccine.
GSK Launches £450M Share Buyback Tranche, Part of £2B Program
GSK has initiated a new £450 million share repurchase tranche, a component of its broader £2 billion capital return program. The company's shares edged higher ahead of the launch.
Haleon Shares Dip as Wellington Discloses 4.97% Stake Ahead of Key Earnings
Haleon's stock declined slightly in London trading after a regulatory filing revealed Wellington Management holds a significant stake. Investors are focused on the company's full-year results due February 25 for updated guidance and capital return plans.
GSK Shares Dip on China Vaccine Timeline and Executive Stock Sales
GSK shares fell 1.5% in early London trading as China's regulatory review for its Arexvy RSV vaccine is set for a 2027 decision. The decline coincided with disclosures of executive share sales to cover tax obligations.
GSK's RSV Vaccine Advances in Chinese Regulatory Review, Eyes 2027 Decision
GSK's Arexvy RSV vaccine application has been accepted for review by China's drug regulator, with a potential approval decision expected in 2027. The stock edged higher as JPMorgan raised its price target and the company's dividend ex-date approaches.
GSK's RSV Vaccine Advances in China Review, Analysts Adjust Targets
GSK's respiratory syncytial virus vaccine Arexvy has entered regulatory review in China, a key market for adult immunization. The stock declined Monday despite several brokerages raising price targets.
GSK Nears 52-Week Peak on COPD Drug Approval and U.S. Pricing Developments
GSK shares advanced 0.6% in London trading, approaching a 52-week high following EU approval for Nucala in COPD and amid U.S. drug discount initiatives. Insider trading activity and the upcoming ex-dividend date remain in focus.
GSK Gains EU Approval for Nucala in COPD, Stock Momentum in Focus
GSK shares rose after EU regulators approved expanded use of Nucala for chronic obstructive pulmonary disease. The stock has surged 17% this week and nearly 49% over the past year.